Published October 2002 | Version v1
Journal article Metadata-only

ZevalinTM: a new radioimmunotherapy agent

Creators

  • 1. Shanghai 6th People's Hospital, Shanghai (China). Dept. of Nuclear Medicine

Description

Radioimmunotherapy is a major component of radionuclide therapy and always being the main field of research. ZevalinTM is the first FDA marketing approved radioimmunotherapy agent which is indicated for the treatment of relapsed or refractory low grade non-Hodgkin's lymphoma. In this review, the component, therapeutic regimen, pharmacological mechanism, radiation dosage and clinical experiment result of ZevalinTM are described respectively

Additional details

Publishing Information

Journal Title
Foreign Medical Sciences. Section of Radiation Medicine and Nuclear Medicine
Journal Volume
26
Journal Issue
5
Journal Page Range
p. 225-227
ISSN
1001-098X

INIS

Country of Publication
China
Country of Input or Organization
China
INIS RN
34043903
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
AMINO ACIDS; ANTIGENS; CHELATING AGENTS; GLYCINE; INDIUM 111; LABELLING; LYMPHOMAS; MONOCLONAL ANTIBODIES; RADIATION DOSES; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; YTTRIUM 90
Descriptors DEC
AMINO ACIDS; ANTIBODIES; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; CARBOXYLIC ACIDS; DAYS LIVING RADIOISOTOPES; DISEASES; DOSES; DRUGS; ELECTRON CAPTURE RADIOISOTOPES; HOURS LIVING RADIOISOTOPES; IMMUNE SYSTEM DISEASES; IMMUNOTHERAPY; INDIUM ISOTOPES; INTERMEDIATE MASS NUCLEI; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; MATERIALS; MEDICINE; MINUTES LIVING RADIOISOTOPES; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ODD-ODD NUCLEI; ORGANIC ACIDS; ORGANIC COMPOUNDS; RADIOACTIVE MATERIALS; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; THERAPY; YTTRIUM ISOTOPES